Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 1/2 2Phase 2/3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Congenital Abnormalities 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × Amsacrine × Clear all
NCT05807932 2024-05-01

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

Heinrich-Heine University, Duesseldorf

Phase 1/2 Recruiting
38 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT00840684 2011-05-13

Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
135 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡